Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AlzProtect & PAREXEL Biotech Enter Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AlzProtect & PAREXEL Biotech Enter Collaboration

For the performance of the clinical phase 2a development of AZP2006 for the treatment of PSP, a rare degenerative disease of the brain

By: Betsy Louda

, Contract Pharma

ALZPROTECT announced that PAREXEL Biotech, a new division of PAREXEL International Corporation, has been selected to perform the clinical phase 2a development of AZP2006 for the treatment of PSP, a rare degenerative disease of the brain. PAREXEL Biotech will fulfill AlzProtect’s needs related to the completion of their Phase 2a clinical study from protocol writing to the coordination of patient recruitment.

 
“It was important for us to work with an internationally renowned partner covering the full range of needs for our first phase 2a clinical trial,” said Philippe Verwaerde, president and scientific director of AlzProtect.
 
“AlzProtect is committed to achieving Phase 2a results in complete confidence. With PAREXEL Biotech, we now have access to the expertise necessary to achieve this goal,” said Laurent Dupire chief operating officer of AlzProtect.
 
“PAREXEL’S recently launched Biotech unit delivers innovative, customized offerings to the biotech community, building on our more than 20 years of experience in this area,” said Jim Anthony, global head of Biotech, PAREXEL. “Our collaboration with AlzProtect is a great example of how we can work together in a unique way, and we look forward to helping advance this important rare disease initiative.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics